Rigel Pharmaceuticals, Inc. (RIGL) EPS Estimated At $-0.18

April 17, 2018 - By Margaret Downey

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) LogoInvestors sentiment increased to 2.06 in Q4 2017. Its up 0.67, from 1.39 in 2017Q3. It increased, as 14 investors sold Rigel Pharmaceuticals, Inc. shares while 18 reduced holdings. 22 funds opened positions while 44 raised stakes. 127.13 million shares or 21.87% more from 104.32 million shares in 2017Q3 were reported.
Ubs Asset Mgmt Americas reported 27,000 shares or 0% of all its holdings. 300 are held by San Francisco Sentry Invest (Ca). Parametric Port Lc has invested 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Sio Capital Mngmt has invested 1.94% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Principal Financial Inc holds 0% or 19,181 shares. Great West Life Assurance Can, Manitoba – Canada-based fund reported 16,712 shares. State Common Retirement Fund holds 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 115,400 shares. Rhenman & Prns Asset holds 1.93M shares or 1.01% of its portfolio. Ghost Tree Lc, a New York-based fund reported 825,000 shares. Teachers Retirement Of The State Of Kentucky stated it has 70,200 shares or 0% of all its holdings. State Street Corp, a Massachusetts-based fund reported 3.99 million shares. First Personal Financial stated it has 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Eam Investors Lc stated it has 0.24% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Goldman Sachs Group Inc accumulated 469,037 shares or 0% of the stock. Swiss National Bank & Trust holds 229,600 shares or 0% of its portfolio.

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.18 EPS on May, 1.They anticipate $0.05 EPS change or 38.46 % from last quarter’s $-0.13 EPS. After having $-0.18 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 5.57% or $0.22 during the last trading session, reaching $3.73. About 3.25M shares traded or 65.52% up from the average. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 9.91% since April 17, 2017 and is uptrending. It has underperformed by 1.64% the S&P500.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 6 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 12 analyst reports since November 6, 2017 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Wednesday, April 4. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Friday, January 19. The company was maintained on Tuesday, March 6 by Cantor Fitzgerald. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Monday, December 11. H.C. Wainwright has “Buy” rating and $7.0 target. The rating was reinitiated by H.C. Wainwright on Monday, November 6 with “Buy”. The company was maintained on Wednesday, March 7 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Friday, February 2 report. The stock has “Buy” rating by Piper Jaffray on Thursday, December 21. The firm has “Buy” rating given on Tuesday, April 3 by H.C. Wainwright. The company was maintained on Tuesday, November 7 by BMO Capital Markets.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $549.69 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.